Target intelligence / Profile preview

Rapidly Proliferating Tissue

Molecular classification: Other

Overview

"Rapidly proliferating tissue" is not a single molecule/receptor but rather describes any population with elevated mitotic activity—including both normal regenerative systems like hematopoiesis and pathological states like metastatic tumors. Therapeutically targeting this property exploits differences between diseased/cancerous versus most adult somatic tissues but also risks collateral toxicity due to overlap with essential regenerative compartments.

Mechanism of action

Inhibition of DNA synthesis or mitotic machinery

Biological functions

Cell proliferationTissue regenerationEmbryonic developmentHematopoiesis

Disease associations

CancerMetastasisInflammation

Safety considerations

MyelosuppressionMucositisOff-target toxicity

Interacting drugs

Chemotherapeutics

2 more in the full profile.

Biomarkers

Ki67PCNA

Beyond the preview

Go deeper on Rapidly Proliferating Tissue.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rapidly Proliferating Tissue.

Explore the full profile